{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:15:22Z","timestamp":1761894922494,"version":"3.44.0"},"reference-count":192,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1053\/j.seminhematol.2009.03.004","type":"journal-article","created":{"date-parts":[[2009,6,22]],"date-time":"2009-06-22T05:37:21Z","timestamp":1245649041000},"page":"230-247","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Antiviral Therapy in Patients With Hematologic Malignancies, Transplantation, and Aplastic Anemia"],"prefix":"10.1053","volume":"46","author":[{"given":"Timothy","family":"Jancel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott R.","family":"Penzak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2009.03.004_bib1","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/0277-5379(89)90089-8","article-title":"Chemoprophylaxis of viral infection in immunocompromised patients","volume":"25","author":"Meyers","year":"1989","journal-title":"Eur J Cancer Clin Oncol"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib2","first-page":"60","article-title":"Prevention of VZV infection in immunosuppressed patients using antiviral agents","volume":"13","author":"Boeckh","year":"2006","journal-title":"Herpes"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib3","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1086\/518938","article-title":"Use of long-term suppressive acyclovir after hematopoietic stem-cell transplantation: impact on herpes simplex virus (HSV) disease and drug-resistant HSV disease","volume":"196","author":"Erard","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib4","doi-asserted-by":"crossref","first-page":"416","DOI":"10.7326\/0003-4819-76-3-112-6-416","article-title":"Herpes simplex virus resistant to acyclovir","volume":"112","author":"Englund","year":"1990","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib5","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1128\/AAC.28.6.740","article-title":"Drug resistance patterns of herpes simplex virus isolates from patients treated with acyclovir","volume":"28","author":"McLaren","year":"1985","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib6","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S0889-8588(05)70110-6","article-title":"Infections in recipients of blood and marrow transplantation","volume":"13","author":"van Burik","year":"1999","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib7","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.1182\/blood.V94.12.4029","article-title":"Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation","volume":"94","author":"Holmberg","year":"1999","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib8","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1182\/blood.V99.6.1978","article-title":"Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study","volume":"99","author":"Junghanss","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib9","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.1182\/blood.V99.12.4357","article-title":"High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution","volume":"99","author":"Chakrabarti","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib10","doi-asserted-by":"crossref","first-page":"173","DOI":"10.7326\/0003-4819-118-3-199302010-00003","article-title":"Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant","volume":"118","author":"Goodrich","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib11","doi-asserted-by":"crossref","first-page":"179","DOI":"10.7326\/0003-4819-118-3-199302010-00004","article-title":"Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial","volume":"118","author":"Winston","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib12","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1182\/blood.V99.4.1159","article-title":"Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation","volume":"99","author":"Reusser","year":"2002","journal-title":"Blood"},{"issue":"Suppl 2","key":"10.1053\/j.seminhematol.2009.03.004_bib13","doi-asserted-by":"crossref","first-page":"S392","DOI":"10.1093\/clinids\/17.Supplement_2.S392","article-title":"Prevention and treatment of cytomegalovirus pneumonia in transplant recipients","volume":"17","author":"Zaia","year":"1993","journal-title":"Clin Infect Dis"},{"issue":"Suppl","key":"10.1053\/j.seminhematol.2009.03.004_bib14","doi-asserted-by":"crossref","first-page":"2S","DOI":"10.1053\/bbmt.2001.v7.pm11777101","article-title":"Diagnosis and epidemiology of community-acquired respiratory virus infections in the immunocompromised host","volume":"7","author":"Englund","year":"2001","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib15","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1182\/blood.V97.4.867","article-title":"Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes","volume":"97","author":"Nichols","year":"2001","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib16","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1182\/blood-2006-12-060343","article-title":"Respiratory virus infection among hematopoietic cell transplant recipients: evidence for asymptomatic parainfluenza virus infection","volume":"110","author":"Peck","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib17","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1365-2141.2008.07295.x","article-title":"The challenge of respiratory virus infections in hematopoietic cell transplant recipients","volume":"143","author":"Boeckh","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib18","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1182\/blood-2003-05-1425","article-title":"The natural history of respiratory syncytial virus infection in cancer and transplant patients: implications for management","volume":"103","author":"Anaissie","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib19","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1016\/j.healun.2005.06.027","article-title":"Intravenous ribavirin is a safe and cost-effective treatment for respiratory syncytial virus infection after lung transplantation","volume":"24","author":"Glanville","year":"2005","journal-title":"J Heart Lung Transplant"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib20","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1097\/INF.0b013e3181343b7e","article-title":"Intravenous palivizumab and ribavirin combination for respiratory syncytial virus disease in high-risk pediatric patients","volume":"26","author":"Ch\u00e1vez-Bueno","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib21","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S1473-3099(03)00515-2","article-title":"Adenovirus: an increasingly important pathogen in paediatric bone marrow transplant patients","volume":"3","author":"Walls","year":"2003","journal-title":"Lancet Infect Dis"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib22","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1128\/CMR.00052-07","article-title":"Adenoviruses in immunocompromised hosts","volume":"21","author":"Echavarr\u00eda","year":"2008","journal-title":"Clin Microbiol Rev"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib23","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/infdis\/169.4.775","article-title":"Increasing incidence of adenovirus disease in bone marrow transplant recipients","volume":"169","author":"Flomenberg","year":"1994","journal-title":"J Infect Dis"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib24","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.3324\/haematol.11279","article-title":"Disseminated adenovirus infections after allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcome","volume":"92","author":"Robin","year":"2007","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib25","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/sj.bmt.1705003","article-title":"Adenovirus infection in paediatric stem cell transplant recipients: increased risk in young children with a delayed immune recovery","volume":"36","author":"van Tol","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib26","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1097\/00006454-200011000-00016","article-title":"Clearance of adenoviral hepatitis with ribavirin therapy in a pediatric liver transplant recipient","volume":"19","author":"Arav-Boger","year":"2000","journal-title":"Pediatr Infect Dis J"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib27","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1086\/319984","article-title":"Treatment of adenovirus infections in patients undergoing allogeneic hematopoietic stem cell transplantation","volume":"32","author":"Bordigoni","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib28","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1053\/bbmt.2001.v7.pm11529489","article-title":"Adenoviral infections and a prospective trial of cidofovir in pediatric hematopoietic stem cell transplantation","volume":"7","author":"Hoffman","year":"2001","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib29","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1093\/ndt\/gfg365","article-title":"Refractory adenovirus infection after simultaneous kidney-pancreas transplantation: successful treatment with intravenous ribavirin and pooled human intravenous immunoglobulin","volume":"18","author":"Emovon","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib30","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1086\/380450","article-title":"Real-time blood plasma polymerase chain reaction for management of disseminated adenovirus infection","volume":"38","author":"Leruez-Ville","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib31","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1086\/498151","article-title":"Clinical and in vitro evaluation of cidofovir for treatment of adenovirus infection in pediatric hematopoietic stem cell transplant recipients","volume":"41","author":"Muller","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib32","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1097\/01.inf.0000091399.29505.21","article-title":"Successful cidofovir treatment of adenovirus-associated hemorrhagic cystitis and renal dysfunction after allogenic bone marrow transplant","volume":"22","author":"Hatakeyama","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib33","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2165\/00003495-199447010-00009","article-title":"Aciclovir","volume":"47","author":"Wagstaff","year":"1994","journal-title":"Drugs"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib34","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0924-8579(96)00339-1","article-title":"Prevention of cytomegalovirus disease","volume":"7","author":"Balfour","year":"1996","journal-title":"Int J Antimicrob Agents"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib35","first-page":"95","article-title":"Prevention and treatment of cytomegalovirus infection after marrow transplantation","volume":"3","author":"Meyers","year":"1988","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib36","doi-asserted-by":"crossref","first-page":"5716","DOI":"10.1073\/pnas.74.12.5716","article-title":"Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine","volume":"74","author":"Elion","year":"1977","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Suppl B","key":"10.1053\/j.seminhematol.2009.03.004_bib37","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/jac\/12.suppl_B.9","article-title":"The biochemistry and mechanism of action of acyclovir","volume":"12","author":"Elion","year":"1983","journal-title":"J Antimicrob Chemother"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib38","doi-asserted-by":"crossref","first-page":"8721","DOI":"10.1016\/S0021-9258(17)34236-9","article-title":"Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound, 9-(2-hydroxyethoxymethyl)guanine","volume":"253","author":"Fyfe","year":"1978","journal-title":"J Biol Chem"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib39","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0166-3542(95)00066-6","article-title":"Valacyclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacy","volume":"28","author":"Beutner","year":"1995","journal-title":"Antiviral Res"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib40","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2165\/00003495-198937030-00002","article-title":"Acyclovir","volume":"37","author":"O'Brien","year":"1989","journal-title":"Drugs"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib41","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0195-6701(96)90010-9","article-title":"Herpesvirus resistance to antiviral drugs: a review of the mechanisms, clinical importance and therapeutic options","volume":"33","author":"Reusser","year":"1996","journal-title":"J Hosp Infect"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib42","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1368-7646(02)00021-3","article-title":"Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms","volume":"5","author":"Gilbert","year":"2002","journal-title":"Drug Resist Updat"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib43","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1001\/jama.1990.03440120084042","article-title":"Treatment of resistant herpes simplex virus with continuous-infusion acyclovir","volume":"263","author":"Engel","year":"1990","journal-title":"JAMA"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib44","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1128\/AAC.35.11.2322","article-title":"In vitro and in vivo characterization of herpes simplex virus clinical isolates recovered from patients infected with human immunodeficiency virus","volume":"35","author":"Hill","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib45","doi-asserted-by":"crossref","first-page":"187","DOI":"10.7326\/0003-4819-112-3-187","article-title":"Acyclovir-resistant varicella zoster virus infection after chronic oral acyclovir therapy in patients with the acquired immunodeficiency syndrome (AIDS)","volume":"112","author":"Jacobson","year":"1990","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib46","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/infdis\/170.1.68","article-title":"Phenotypic and genotypic characterization of acyclovir-resistant varicella-zoster viruses isolated from persons with AIDS","volume":"170","author":"Boivin","year":"1994","journal-title":"J Infect Dis"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib47","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1099\/0022-1317-64-3-523","article-title":"Characterization of abnormal thymidine kinases induced by drug-resistant strains of herpes simplex virus type 1","volume":"64","author":"Larder","year":"1983","journal-title":"J Gen Virol"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib48","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/0002-9343(82)90088-2","article-title":"Overview of acyclovir pharmacokinetic disposition in adults and children","volume":"73","author":"Blum","year":"1982","journal-title":"Am J Med"},{"issue":"Suppl B","key":"10.1053\/j.seminhematol.2009.03.004_bib49","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/jac\/12.suppl_B.29","article-title":"Pharmacokinetics of acyclovir after intravenous and oral administration","volume":"12","author":"de Miranda","year":"1983","journal-title":"J Antimicrob Chemother"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib50","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1128\/AAC.39.12.2759","article-title":"Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans","volume":"39","author":"Soul-Lawton","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib51","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2165\/00003088-198308030-00001","article-title":"Clinical pharmacokinetics of acyclovir","volume":"8","author":"Laskin","year":"1983","journal-title":"Clin Pharmacokinet"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib52","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/clpt.1993.196","article-title":"Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers","volume":"54","author":"Weller","year":"1993","journal-title":"Clin Pharmacol Ther"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib53","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1086\/513804","article-title":"A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection","volume":"177","author":"Feinberg","year":"1998","journal-title":"J Infect Dis"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib54","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1097\/00007611-199412000-00006","article-title":"Acyclovir neurotoxicity: clinical experience and review of the literature","volume":"87","author":"Adair","year":"1994","journal-title":"South Med J"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib55","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2165\/00148581-200810020-00008","article-title":"Determinants of aciclovir-induced nephrotoxicity in children","volume":"10","author":"Schreiber","year":"2008","journal-title":"Paediatr Drugs"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib56","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/01.aids.0000162333.35686.4c","article-title":"Renal tubular transporters and antiviral drugs: an update","volume":"19","author":"Izzedine","year":"2005","journal-title":"AIDS"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib57","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/sj.bmt.1703817","article-title":"Clinical utility of oral valacyclovir compared with oral acyclovir for the prevention of herpes simplex virus mucositis following autologous bone marrow transplantation or stem cell rescue therapy","volume":"31","author":"Eisen","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib58","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1128\/AAC.18.3.443","article-title":"In vitro susceptibility of varicella-zoster virus to acyclovir","volume":"18","author":"Biron","year":"1980","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib59","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/jac\/37.2.303","article-title":"Activity of penciclovir in antiviral assays against herpes simplex virus","volume":"37","author":"Bacon","year":"1996","journal-title":"J Antimicrob Chemother"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib60","doi-asserted-by":"crossref","first-page":"396","DOI":"10.2165\/00003495-199550020-00011","article-title":"Famciclovir","volume":"50","author":"Perry","year":"1995","journal-title":"Drugs"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib61","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1128\/AAC.36.9.2037","article-title":"In vitro activities of penciclovir and acyclovir against herpes simplex virus types 1 and 2","volume":"36","author":"Weinberg","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib62","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0166-0934(95)01889-1","article-title":"Comparison of a DNA probe assay with the plaque reduction assay for measuring the sensitivity of herpes simplex virus and varicella-zoster virus to penciclovir and acyclovir","volume":"56","author":"Standring-Cox","year":"1996","journal-title":"J Virol Methods"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib63","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1128\/AAC.31.8.1238","article-title":"Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxy-methylbut-1-yl)guanine (BRL 39123) in cell culture","volume":"31","author":"Boyd","year":"1987","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib64","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/chir.530050804","article-title":"Use of isotopically chiral [4\u2032-13C]penciclovir and 13C NMR to determine the specificity and absolute configuration of penciclovir phosphate esters formed in HSV-1 and HSV-2 infected cells and by HSV-1-encoded thymidine kinase","volume":"5","author":"Vere Hodge","year":"1993","journal-title":"Chirality"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib65","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1128\/AAC.33.10.1765","article-title":"Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-l-yl)guanine; penciclovir]","volume":"33","author":"Vere Hodge","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib66","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1007\/s00705-003-0124-7","article-title":"Profiling penciclovir susceptibility and prevalence of resistance of herpes simplex virus isolates across eleven clinical trials","volume":"148","author":"Sarisky","year":"2003","journal-title":"Arch Virol"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib67","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1128\/AAC.32.3.358","article-title":"Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxymethylbut-1-yl) guanine (BRL 39123) in animals","volume":"32","author":"Boyd","year":"1988","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2009.03.004_bib68","first-page":"14","article-title":"The pharmacological profile of famciclovir","volume":"15","author":"Crumpacker","year":"1996","journal-title":"Semin Dermatol"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib69","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/clpt.1994.51","article-title":"Pharmacokinetics of famciclovir in subjects with varying degrees of renal impairment","volume":"55","author":"Boike","year":"1994","journal-title":"Clin Pharmacol Ther"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib70","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1177\/09563202930040S602","article-title":"Pharmacokinetics of famciclovir in man","volume":"4","author":"Pue","year":"1993","journal-title":"Antiv Chem Chemother"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib71","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/jac\/33.1.119","article-title":"Linear pharmacokinetics of penciclovir following administration of single oral doses of famciclovir 125, 250, 500 and 750 mg to healthy volunteers","volume":"33","author":"Pue","year":"1994","journal-title":"J Antimicrob Chemother"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib72","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1128\/AAC.38.10.2454","article-title":"Safety of famciclovir in patients with herpes zoster and genital herpes","volume":"38","author":"Saltzman","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib73","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1081\/CNV-100000070","article-title":"A randomized, double-blind trial of famciclovir versus acyclovir for the treatment of localized dermatomal herpes zoster in immunocompromised patients","volume":"19","author":"Tyring","year":"2001","journal-title":"Cancer Invest"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib74","doi-asserted-by":"crossref","first-page":"21","DOI":"10.7326\/0003-4819-128-1-199801010-00004","article-title":"Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons","volume":"128","author":"Schacker","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib75","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1097\/00002030-200006160-00019","article-title":"Efficacy and safety of famciclovir for treating mucocutaneous herpes simplex infection in HIV-infected individuals","volume":"14","author":"Romanowski","year":"2000","journal-title":"AIDS"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib76","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.2165\/00003495-200161080-00013","article-title":"Valganciclovir","volume":"61","author":"Curran","year":"2001","journal-title":"Drugs"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib77","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/358162a0","article-title":"A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells","volume":"358","author":"Sullivan","year":"1992","journal-title":"Nature"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib78","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1034\/j.1399-3062.1999.010204.x","article-title":"Antiviral drug resistance in human cytomegalovirus","volume":"1","author":"Chou","year":"1999","journal-title":"Transpl Infect Dis"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib79","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/jmv.20471","article-title":"Analysis of cytomegalovirus DNA polymerase (UL54) mutations in solid organ transplant patients receiving valganciclovir or ganciclovir prophylaxis","volume":"77","author":"Boivin","year":"2005","journal-title":"J Med Virol"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib80","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.antiviral.2006.05.002","article-title":"Antiviral drugs for cytomegalovirus diseases","volume":"71","author":"Biron","year":"2006","journal-title":"Antiviral Res"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib81","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/QCO.0b013e328307c7b4","article-title":"Update in management of ganciclovir-resistant cytomegalovirus infection","volume":"21","author":"Avery","year":"2008","journal-title":"Curr Opin Infect Dis"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib82","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2165\/00003088-199937020-00005","article-title":"Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers","volume":"37","author":"Brown","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib83","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1067\/mcp.2002.126306","article-title":"Pharmacokinetics of valganciclovir and ganciclovir in renal impairment","volume":"72","author":"Czock","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib84","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2165\/00003495-199856010-00012","article-title":"Ganciclovir","volume":"56","author":"Noble","year":"1998","journal-title":"Drugs"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib85","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa011759","article-title":"A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis","volume":"346","author":"Martin","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib86","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1600-6143.2004.00382.x","article-title":"Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients","volume":"4","author":"Paya","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib87","doi-asserted-by":"crossref","first-page":"859","DOI":"10.2165\/00003495-200565060-00012","article-title":"Valganciclovir: a review of its use in the management of CMV infection and disease in immunocompromised patients","volume":"65","author":"Cvetkovi\u0107","year":"2005","journal-title":"Drugs"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib88","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/01.TP.0000146844.65273.62","article-title":"Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease","volume":"79","author":"Singh","year":"2005","journal-title":"Transplantation"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib89","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1111\/j.1600-6143.2005.00866.x","article-title":"A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients","volume":"5","author":"Humar","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib90","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1600-6143.2007.02026.x","article-title":"A survey of CMV prevention strategies after liver transplantation","volume":"8","author":"Levitsky","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib91","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM199204303261803","article-title":"A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation","volume":"326","author":"Merigan","year":"1992","journal-title":"N Engl J Med"},{"year":"2006","series-title":"Valcyte","key":"10.1053\/j.seminhematol.2009.03.004_bib92"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib93","doi-asserted-by":"crossref","first-page":"257","DOI":"10.7326\/0003-4819-126-4-199702150-00001","article-title":"Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS","volume":"126","author":"Lalezari","year":"1997","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib94","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/nrd1877","article-title":"Acyclic nucleoside phosphonates: a key class of antiviral drugs","volume":"4","author":"De Clercq","year":"2005","journal-title":"Nat Rev Drug Discov"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib95","doi-asserted-by":"crossref","first-page":"5927","DOI":"10.1128\/JVI.72.7.5927-5936.1998","article-title":"Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments","volume":"72","author":"Cihlar","year":"1998","journal-title":"J Virol"},{"issue":"Suppl","key":"10.1053\/j.seminhematol.2009.03.004_bib96","first-page":"S29","article-title":"Treatment of acyclovir resistant herpes simplex virus infections in patients with AIDS","volume":"5","author":"Safrin","year":"1992","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib97","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1128\/AAC.39.6.1247","article-title":"Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients","volume":"39","author":"Cundy","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib98","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0166-3542(95)00829-2","article-title":"Pharmacokinetics, safety and bioavailability of cidofovir in HIV-infected subjects","volume":"29","author":"Wachsman","year":"1996","journal-title":"Antiviral Res"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib99","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2165\/00003088-199936020-00004","article-title":"Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir","volume":"36","author":"Cundy","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib100","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1681\/ASN.V113383","article-title":"Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1","volume":"11","author":"Ho","year":"2000","journal-title":"J Am Soc Nephrol"},{"year":"2000","series-title":"Vistide","key":"10.1053\/j.seminhematol.2009.03.004_bib101"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib102","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2165\/00003088-198106020-00004","article-title":"Clinical pharmacokinetics of probenecid","volume":"6","author":"Cunningham","year":"1981","journal-title":"Clin Pharmacokinet"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib103","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1182\/blood.V97.2.388","article-title":"Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients","volume":"97","author":"Ljungman","year":"2001","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib104","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jcv.2005.02.009","article-title":"Cidofovir for cytomegalovirus reactivation in pediatric patients after hematopoietic stem cell transplantation","volume":"34","author":"Cesaro","year":"2005","journal-title":"J Clin Virol"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib105","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1086\/505498","article-title":"Adenovirus infections in transplant recipients","volume":"43","author":"Ison","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib106","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1086\/319352","article-title":"Adenovirus infections in adult recipients of blood and marrow transplants","volume":"32","author":"La Rosa","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib107","first-page":"21","article-title":"Pharmacokinetics of cidofovir in renal insufficiency and in continuous ambulatory peritoneal dialysis or high-flux hemodialysis","volume":"65","author":"Brody","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib108","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1016\/0002-9343(92)90329-A","article-title":"Mechanism of action of foscarnet against viral polymerases","volume":"92","author":"Crumpacker","year":"1992","journal-title":"Am J Med"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib109","doi-asserted-by":"crossref","first-page":"104","DOI":"10.2165\/00003495-199141010-00009","article-title":"Foscarnet","volume":"41","author":"Chrisp","year":"1991","journal-title":"Drugs"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib110","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1086\/368385","article-title":"Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis","volume":"187","author":"Weinberg","year":"2003","journal-title":"J Infect Dis"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib111","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.healun.2007.09.012","article-title":"A single-center experience with ganciclovir-resistant cytomegalovirus in lung transplant recipients: treatment and outcome","volume":"26","author":"Reddy","year":"2007","journal-title":"J Heart Lung Transplant"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib112","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1002\/jmv.21277","article-title":"Case report: persistent cytomegalovirus (CMV) infection after haploidentical hematopoietic stem cell transplantation using in vivo alemtuzumab: emergence of resistant CMV due to mutations in the UL97 and UL54 genes","volume":"80","author":"Oshima","year":"2008","journal-title":"J Med Virol"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib113","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/clpt.1988.114","article-title":"Pharmacokinetics and absorption of foscarnet after intravenous and oral administration to patients with human immunodeficiency virus","volume":"44","author":"Sj\u00f6vall","year":"1988","journal-title":"Clin Pharmacol Ther"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib114","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1128\/AAC.33.7.1023","article-title":"Pharmacokinetics of foscarnet and distribution to cerebrospinal fluid after intravenous infusion in patients with human immunodeficiency virus infection","volume":"33","author":"Sj\u00f6vall","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib115","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1128\/AAC.33.5.742","article-title":"Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis","volume":"33","author":"Aweeka","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib116","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3109\/inf.1985.17.issue-2.06","article-title":"Intravenous foscarnet for the treatment of severe cytomegalovirus infection in allograft recipients","volume":"17","author":"Klintmalm","year":"1985","journal-title":"Scand J Infect Dis"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib117","first-page":"77","article-title":"Management of CMV infection and disease in transplant patients","volume":"11","author":"Razonable","year":"2004","journal-title":"Herpes"},{"issue":"Suppl 2","key":"10.1053\/j.seminhematol.2009.03.004_bib118","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1034\/j.1399-3062.2001.00004.x","article-title":"Cytomegalovirus drug resistance and clinical implications","volume":"3","author":"Chou","year":"2001","journal-title":"Transpl Infect Dis"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib119","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2165\/00003088-199937060-00003","article-title":"Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802","volume":"37","author":"He","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib120","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1056\/NEJMra050740","article-title":"Neuraminidase inhibitors for influenza","volume":"353","author":"Moscona","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib121","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1128\/AAC.42.3.640","article-title":"Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS4071 protects mice and ferrets against influenza infection","volume":"42","author":"Mendel","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib122","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1128\/AAC.47.7.2264-2272.2003","article-title":"Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir","volume":"47","author":"McKimm-Breschkin","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib123","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0166-3542(01)00124-3","article-title":"Position statement: global neuraminidase inhibitor susceptibility network","volume":"49","author":"Zambon","year":"2001","journal-title":"Antiviral Res"},{"year":"2008","series-title":"Tamiflu","key":"10.1053\/j.seminhematol.2009.03.004_bib125"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib126","series-title":"Applied pharmacokinetics: principles of therapeutic drug monitoring","first-page":"9.1","article-title":"Special pharmacokinetic considerations in the elderly","author":"Mayersohn","year":"1992"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib127","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1124\/dmd.108.024018","volume":"37","author":"Ose","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib128","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1124\/dmd.107.017699","article-title":"Oseltamivir (Tamiflu) efflux transport at the blood-brain barrier via P-glycoprotein","volume":"36","author":"Morimoto","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib129","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1124\/dmd.30.1.13","article-title":"The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies","volume":"30","author":"Hill","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib130","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1128\/AAC.00047-08","article-title":"Pharmacokinetics and tolerability of oseltamivir combined with probenecid","volume":"52","author":"Holodniy","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib131","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1177\/0091270008320317","article-title":"Population pharmacokinetics of oseltamivir when coadministered with probenecid","volume":"48","author":"Rayner","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib132","doi-asserted-by":"crossref","first-page":"787","DOI":"10.2165\/00002018-200326110-00004","article-title":"Safety and pharmacology of oseltamivir in clinical use","volume":"26","author":"Dutkowski","year":"2003","journal-title":"Drug Safety"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib133","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1345\/aph.10118","article-title":"Neuraminidase inhibitors: zanamivir and oseltamivir","volume":"35","author":"McNicholl","year":"2001","journal-title":"Ann Pharmacother"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib134","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1128\/AAC.37.7.1473","article-title":"4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro","volume":"37","author":"Woods","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib135","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/363418a0","article-title":"Rational design of potent sialidase-based inhibitors of influenza virus replication","volume":"363","author":"von Itzstein","year":"1993","journal-title":"Nature"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib136","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0166-3542(94)90101-5","article-title":"Anti-influenza virus activity of the neuraminidase inhibitor 4-guanidino-Neu5Ac2en in cell culture and in human respiratory epithelium","volume":"25","author":"Hayden","year":"1994","journal-title":"Antiviral Res"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib137","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2165\/00003495-200262010-00004","article-title":"Zanamivir: An update of its use in influenza","volume":"62","author":"Cheer","year":"2002","journal-title":"Drugs"},{"year":"2008","series-title":"Relenza","key":"10.1053\/j.seminhematol.2009.03.004_bib138"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib139","doi-asserted-by":"crossref","first-page":"761","DOI":"10.2165\/00003495-199958040-00016","article-title":"Zanamivir: A review of its use in influenza","volume":"58","author":"Dunn","year":"1999","journal-title":"Drugs"},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2009.03.004_bib140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003088-199936001-00001","article-title":"Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers","volume":"36","author":"Cass","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib141","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1177\/00912700022008900","article-title":"A population pharmacokinetic analysis of zanamivir in subjects with experimental and naturally occurring influenza: effects of formulation and route of administration","volume":"40","author":"Peng","year":"2000","journal-title":"J Clin Pharmacol"},{"issue":"Supp1 1","key":"10.1053\/j.seminhematol.2009.03.004_bib142","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2165\/00003088-199936001-00003","article-title":"Pharmacoscintigraphic evaluation of lung deposition of inhaled zanamivir in healthy volunteers","volume":"36","author":"Cass","year":"1999","journal-title":"Clin Pharmacokinet"},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2009.03.004_bib143","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2165\/00003088-199936001-00002","article-title":"Effect of renal impairment on the pharmacokinetics of intravenous zanamivir","volume":"36","author":"Cass","year":"1999","journal-title":"Clin Pharmacokinet"},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2009.03.004_bib144","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2165\/00003088-199936001-00005","article-title":"The low potential for drug interactions with zanamivir","volume":"36","author":"Daniel","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib145","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2165\/00002018-199921040-00003","article-title":"Zanamivir: A review of clinical safety","volume":"21","author":"Freund","year":"1999","journal-title":"Drug Saf"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib146","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.2165\/00002018-200124150-00003","article-title":"Zanamivir: a review of clinical safety in individuals at high risk of developing influenza-related complications","volume":"24","author":"Gravenstein","year":"2001","journal-title":"Drug Saf"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib147","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(06)67970-1","article-title":"Antivirals for influenza in healthy adults: systematic review","volume":"367","author":"Jefferson","year":"2006","journal-title":"Lancet"},{"year":"2007","series-title":"Symmetrel","key":"10.1053\/j.seminhematol.2009.03.004_bib148"},{"year":"2006","series-title":"Flumadine","key":"10.1053\/j.seminhematol.2009.03.004_bib149"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib150","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2165\/00003088-198713030-00002","article-title":"Clinical pharmacokinetics of anti-parkinsonian drugs","volume":"13","author":"Cedarbaum","year":"1987","journal-title":"Clin Pharmacokinet"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib151","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2165\/00003088-198814010-00003","article-title":"Clinical pharmacokinetics of amantadine hydrochloride","volume":"14","author":"Aoki","year":"1988","journal-title":"Clin Pharmacokinet"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib152","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/j.1365-2125.1976.tb00642.x","article-title":"Effect of amantadine on drug-induced parkinsonism: relationship between plasma levels and effect","volume":"3","author":"Pacifici","year":"1976","journal-title":"Br J Clin Pharmacol"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib153","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.1532-5415.1975.tb00187.x","article-title":"Visual hallucinations and delirium during treatment with amantadine","volume":"23","author":"Postma","year":"1975","journal-title":"J Am Geriatr Soc"},{"year":"2008","series-title":"Wellbutrin XL","key":"10.1053\/j.seminhematol.2009.03.004_bib154"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib155","first-page":"974","article-title":"Amantadine\u2013Dyazide interaction","volume":"129","author":"Wilson","year":"1983","journal-title":"Can Med Assoc J"},{"year":"2004","series-title":"K-Dur","key":"10.1053\/j.seminhematol.2009.03.004_bib156"},{"year":"2005","series-title":"Klor-con","key":"10.1053\/j.seminhematol.2009.03.004_bib157"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib158","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1177\/106002809502900312","article-title":"Rimantadine: a clinical perspective","volume":"29","author":"Wintermeyer","year":"1995","journal-title":"Ann Pharmacother"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib159","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1128\/AAC.31.7.1140","article-title":"Pharmacokinetics of a single dose of rimantadine in young adults and children","volume":"31","author":"Anderson","year":"1987","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib160","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/clpt.1987.176","article-title":"Pharmacokinetics of rimantadine hydrochloride in patients with chronic liver disease","volume":"42","author":"Wills","year":"1987","journal-title":"Clin Pharmacol Ther"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib161","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1086\/499819","article-title":"Bad bugs need drugs: an update on the development pipeline from the antimicrobial availability task force of the Infectious Diseases Society of America","volume":"42","author":"Talbot","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib162","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1128\/AAC.46.8.2365-2372.2002","article-title":"Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action","volume":"46","author":"Biron","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib163","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1128\/AAC.46.9.2969-2976.2002","article-title":"Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding","volume":"46","author":"Lalezari","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib164","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1128\/AAC.47.4.1334-1342.2003","article-title":"Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects","volume":"47","author":"Wang","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib165","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jcv.2006.07.010","article-title":"Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet","volume":"37","author":"Drew","year":"2006","journal-title":"J Clin Virol"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib168","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0166-3542(03)00110-4","article-title":"Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney","volume":"59","author":"Ciesla","year":"2003","journal-title":"Antiviral Res"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib169","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1128\/AAC.49.2.656-662.2005","article-title":"Comparison of the antiviral activities of alkoxyalkyl and alkyl esters of cidofovir against human and murine cytomegalovirus replication in vitro","volume":"49","author":"Wan","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib171","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1093\/jac\/dkm376","article-title":"Preclinical development of bicyclic nucleoside analogues as potent and selective inhibitors of varicella zoster virus","volume":"60","author":"McGuigan","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib172","first-page":"40","article-title":"A single accelerating dose study to evaluate safety and pharmacokinetics (PK) of FV-100 in healthy subjects","volume":"A32","author":"Canas","year":"2008","journal-title":"Antiviral Res"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib173","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1128\/AAC.46.6.1766-1772.2002","article-title":"Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY 57-1293","volume":"46","author":"Betz","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib174","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1177\/095632020701800104","article-title":"Superior efficacy of helicase-primase inhibitor BAY 57-1293 for herpes infection and latency in the guinea pig model of human genital herpes disease","volume":"18","author":"Baumeister","year":"2007","journal-title":"Antivir Chem Chemother"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib175","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.antiviral.2006.11.006","article-title":"The helicase primase inhibitor, BAY 57-1293 shows potent therapeutic antiviral activity superior to famciclovir in BALB\/c mice infected with herpes simplex virus type 1","volume":"75","author":"Biswas","year":"2007","journal-title":"Antiviral Res"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib176","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/nm0402-386","article-title":"Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease","volume":"8","author":"Crute","year":"2002","journal-title":"Nat Med"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib177","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/nm0402-392","article-title":"New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease","volume":"8","author":"Kleymann","year":"2002","journal-title":"Nat Med"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib178","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1128\/AAC.00211-07","article-title":"RSV604, a novel inhibitor of respiratory syncytial virus replication","volume":"51","author":"Chapman","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib180","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1128\/AAC.43.7.1616","article-title":"Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection","volume":"43","author":"Calfee","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib181","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1128\/AAC.45.12.3403-3408.2001","article-title":"Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants","volume":"45","author":"Gubareva","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib182","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.antiviral.2005.10.002","article-title":"Anti-influenza virus activity of peramivir in mice with single intramuscular injection","volume":"69","author":"Bantia","year":"2006","journal-title":"Antiviral Res"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib183","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.antiviral.2008.01.003","article-title":"Current and future antiviral therapy of severe seasonal and avian influenza","volume":"78","author":"Beigel","year":"2008","journal-title":"Antiviral Res"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib184","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.virol.2007.12.029","article-title":"Injectable peramivir mitigates disease and promotes survival in ferrets and mice infected with the highly virulent influenza virus, A\/Vietnam\/1203\/04 (H5N1)","volume":"374","author":"Yun","year":"2008","journal-title":"Virology"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib185","doi-asserted-by":"crossref","first-page":"4542","DOI":"10.1128\/AAC.48.12.4542-4549.2004","article-title":"Potent and long-acting dimeric inhibitors of influenza virus neuraminidase are effective at a once-weekly dosing regimen","volume":"48","author":"Macdonald","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib187","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1128\/AAC.46.4.977-981.2002","article-title":"In vitro and in vivo activities of anti-influenza virus compound T-705","volume":"46","author":"Furuta","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib188","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1128\/AAC.49.3.981-986.2005","article-title":"Mechanism of action of T-705 against influenza virus","volume":"49","author":"Furuta","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib189","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1128\/AAC.01051-06","article-title":"Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice","volume":"51","author":"Sidwell","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib190","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1128\/AAC.50.4.1470-1479.2006","article-title":"Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection","volume":"50","author":"Malakhov","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib191","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1086\/522609","article-title":"DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection","volume":"196","author":"Belser","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib192","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/nm0402-386","article-title":"Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease","volume":"8","author":"Crute","year":"2002","journal-title":"Nat Med"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib193","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/nm0402-392","article-title":"New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease","volume":"8","author":"Kleymann","year":"2002","journal-title":"Nat Med"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib194","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1517\/14728214.13.3.393","article-title":"Emerging antiviral drugs","volume":"13","author":"De Clercq","year":"2008","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib195","doi-asserted-by":"crossref","first-page":"7271","DOI":"10.1128\/JVI.73.9.7271-7277.1999","article-title":"Inhibition of Epstein-Barr virus replication by a benzimidazole L-riboside: novel antiviral mechanism of 5, 6-dichloro-2-(isopropylamino)-1-beta-L-ribofuranosyl-1H benzamidazole","volume":"73","author":"Zacny","year":"1999","journal-title":"J Virol"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib196","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/rmv.574","article-title":"Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir","volume":"18","author":"Chou","year":"2008","journal-title":"Rev Med Virol"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib197","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1128\/JVI.01787-07","article-title":"Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant","volume":"82","author":"Chou","year":"2008","journal-title":"J Virol"},{"key":"10.1053\/j.seminhematol.2009.03.004_bib198","doi-asserted-by":"crossref","first-page":"5403","DOI":"10.1182\/blood-2007-11-121558","article-title":"Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study","volume":"111","author":"Winston","year":"2008","journal-title":"Blood"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196309000596?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196309000596?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:21:25Z","timestamp":1758522085000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196309000596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7]]},"references-count":192,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["S0037196309000596"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2009.03.004","relation":{},"ISSN":["0037-1963"],"issn-type":[{"type":"print","value":"0037-1963"}],"subject":[],"published":{"date-parts":[[2009,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiviral Therapy in Patients With Hematologic Malignancies, Transplantation, and Aplastic Anemia","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2009.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}